Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19553462 | 0.89 | CDK1 (0.53) | HSP90AB1HSP90AA1 | |
| SCHEMBL19553607 | 0.88 | CNR2 (0.40) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL19553815 | 0.88 | CNR2 (0.42) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL19553686 | 0.85 | CDK1 (0.49) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL9366819 | 0.83 | MEN1 (0.56) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL19553675 | 0.83 | CNR2 (0.37) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL9115728 | 0.82 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL19553495 | 0.82 | CNR2 (0.36) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL19553680 | 0.82 | CNR2 (0.36) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL9116660 | 0.81 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| CN-109311882-B | Adenine derivatives as protein kinase inhibitors | BCI制药公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| EP-3452477-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. Pharma (BE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191297-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | BCI PHARMA (FR) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | HSP90AB1 3089/4885HSP90AA1 3149/4885HDAC6 2991/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | HSP90AB1 3089/4885HSP90AA1 3149/4885HDAC6 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.